Search Results - campbell+mcinnes

4 Results

Sort By:

Abbapolins as Inhibitors and Degraders of Polo-Like Kinases

Reference #: 01593 The University of South Carolina is offering licensing opportunities for Abbapolins as Inhibitors and Degraders of Polo-Like Kinases Background: There are no effective treatments for castration-resistant prostate cancers as all current therapies eventually fail. Invention Description: Novel chemicals called abbapolins are described...

Published: 4/2/2024 | Inventor(s): Campbell Mcinnes, Michael Wyatt, Danda Chapagai, Jessy Stafford, Gursanker Ramamoorthy

Keywords(s): abbapolin, drug discovery, peptide, Polo Like Kinase

Category(s): Biomedical and Life Sciences, Health Sciences

Macrocyclic Dimerization Inhibitors of Raf Kinases

Reference #: 01338The University of South Carolina is offering licensing opportunities for Macrocyclic Dimerization Inhibitors of Raf Kinases.Background:Despite the clinical success of B-Raf inhibitors like vemurafenib in treating metastatic melanoma, resistance has emerged through “paradoxical MEK/ERK signaling” where rather than blocking...

Published: 12/15/2023 | Inventor(s): Campbell Mcinnes

Keywords(s):

Category(s): Chemistry and Biochemistry, Biomedical and Life Sciences, Health Sciences

Selective Inhibition of the Polo-Like Kinase 1 PBD for Cancer Therapy

Reference #1307: Selective Inhibition of the Polo-Like Kinase 1 PBD for Cancer TherapyThe University of South Carolina is offering licensing opportunities for the Selective Inhibition of the Polo-Like Kinase 1 PBD for Cancer Therapy.Background:Polo-like kinase 1 (PLK1) has been shown to be over-expressed in a number of tumors. Its expression has been...

Published: 9/4/2022 | Inventor(s): Campbell Mcinnes

Keywords(s):

Category(s): Chemistry and Biochemistry, Biomedical and Life Sciences, Health Sciences

Structural Analysis of the CDK4/cyclin D1 Substrate Recognition Site and Basis for p27 and Inhibitor Binding

Reference #: 00829 Invention Description: An alternative strategy for inhibition of the cyclin dependent kinases in anti-tumor drug discovery is afforded through the substrate recruitment site on the cyclin positive regulatory subunit. This approach offers the potential for generating cell cycle-specific CDK inhibitors and to reduce the inhibition...

Published: 9/2/2022 | Inventor(s): Campbell Mcinnes, Shu Liu

Keywords(s):

Category(s): Biomedical and Life Sciences